- Home
- UTG vs SLNO Comparison
UTG vs SLNO Comparison
Compare UTG & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTG
- SLNO
- Stock Information
- Founded
- UTG 2003
- SLNO 1999
- Country
- UTG United States
- SLNO United States
- Employees
- UTG N/A
- SLNO N/A
- Industry
- UTG Investment Managers
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- UTG Finance
- SLNO Health Care
- Exchange
- UTG Nasdaq
- SLNO Nasdaq
- Market Cap
- UTG 3.4B
- SLNO 3.8B
- IPO Year
- UTG N/A
- SLNO 2014
- Fundamental
- Price
- UTG $37.29
- SLNO $69.77
- Analyst Decision
- UTG
- SLNO Strong Buy
- Analyst Count
- UTG 0
- SLNO 10
- Target Price
- UTG N/A
- SLNO $112.50
- AVG Volume (30 Days)
- UTG 317.8K
- SLNO 1.6M
- Earning Date
- UTG 01-01-0001
- SLNO 11-05-2025
- Dividend Yield
- UTG 7.28%
- SLNO N/A
- EPS Growth
- UTG N/A
- SLNO N/A
- EPS
- UTG 9.86
- SLNO N/A
- Revenue
- UTG $96,107,593.00
- SLNO $32,656,999.00
- Revenue This Year
- UTG N/A
- SLNO N/A
- Revenue Next Year
- UTG N/A
- SLNO $175.39
- P/E Ratio
- UTG $3.20
- SLNO N/A
- Revenue Growth
- UTG 8.35
- SLNO N/A
- 52 Week Low
- UTG $25.26
- SLNO $41.50
- 52 Week High
- UTG $35.29
- SLNO $90.32
- Technical
- Relative Strength Index (RSI)
- UTG 40.83
- SLNO 42.02
- Support Level
- UTG $37.05
- SLNO $65.85
- Resistance Level
- UTG $38.49
- SLNO $70.12
- Average True Range (ATR)
- UTG 0.48
- SLNO 2.55
- MACD
- UTG -0.17
- SLNO 0.27
- Stochastic Oscillator
- UTG 25.14
- SLNO 63.97
About UTG Reaves Utility Income Fund of Beneficial Interest
Reaves Utility Income Fund is a closed-end management investment company. The company's investment objective is to provide a high level of after-tax income and total return consisting of tax-advantaged dividend income and capital appreciation. It invests a portion of its total assets in securities of utility companies, which may include companies in the electric, gas, water, telecommunications sectors, as well as other companies engaged in other infrastructure operations.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.